Gide has advised Inovo Fund III SCSp on its participation in a EUR 9 million seed investment round for Ingenix that also saw the OTB Ventures and the International Finance Corporation invest. DLA Piper advised Ingenix.
Inovo Fund III SCSp is a fund owned by Inovo.vc.
Ingenix.ai is a biotech company developing a foundational model for clinical trials. According to DLA Piper, the funding will enable "Ingenix to further develop its advanced AI platform, potentially revolutionizing the way clinical trials are conducted worldwide. Ingenix's proprietary model analyses biological phenomena at the molecular, cellular, and population levels, enabling clinical trial outcomes to be predicted with unprecedented accuracy."
The Gide team included Partner Pawel Grzeskowiak, Counsel Wojciech Czyzewski, and Associates Magdalena Zawislak and Mateusz Wieckowski.
The DLA Piper team included Warsaw-based Partner Rafal Kluziak, Counsels Wojciech Kalinowski and Anna Chrabota-Bajson, and Junior Associates Michal Bandurski and Konrad Nazarowski as well as further lawyers in Leeds and London.
